ESL:F:F-EssilorLuxottica Société anonyme (EUR)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 209

Change

+1.60 (+0.77)%

Market Cap

USD 92.21B

Volume

398.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-17 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
IUI1:F Intuitive Surgical Inc

N/A

USD 141.14B
ESLC:F ESSILORLUXOTTICA 1/2/O.N.

N/A

USD 95.12B
BOX:F Becton Dickinson and Company

N/A

USD 62.42B
HYB0:F HOYA CORP. ADR/ 1 O.N.

N/A

USD 39.34B
HYB:F HOYA Corporation

N/A

USD 38.54B
RMEA:F Resmed Inc DRC

N/A

USD 29.01B
RME:F ResMed Inc

N/A

USD 28.44B
CBHD:F Coloplast A/S

N/A

USD 25.77B
CBH:F COLOPLAST SP.ADR 1/10 DK1

N/A

USD 25.37B
TUO:F Terumo Corporation

N/A

USD 23.32B

ETFs Containing ESL:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.01% 83% B 74% C
Dividend Return 2.17% 70% C- 48% F
Total Return 17.19% 77% C+ 71% C-
Trailing 12 Months  
Capital Gain 13.28% 85% B 65% D
Dividend Return 3.89% 72% C 41% F
Total Return 17.17% 77% C+ 62% D
Trailing 5 Years  
Capital Gain 90.87% 92% A 83% B
Dividend Return 9.47% 62% D 37% F
Total Return 100.34% 84% B 72% C
Average Annual (5 Year Horizon)  
Capital Gain 11.63% 82% B 78% C+
Dividend Return 12.38% 75% C 73% C
Total Return 0.75% 53% F 29% F
Risk Return Profile  
Volatility (Standard Deviation) 19.90% 58% F 59% D-
Risk Adjusted Return 62.22% 93% A 88% B+
Market Capitalization 92.21B 98% N/A 98% N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.